Different Inhibitors of Aβ42-Induced Toxicity Have Distinct Metal-Ion Dependency
Ashley J Mason1, Ian Hurst1, Ravinder Malik1
1Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, United States.
Abstract:
Oligomers of amyloid β-protein (Aβ) are thought to be the proximal toxic agents initiating the neuropathologic process in Alzheimer's disease (AD). Therefore, targeting the self-assembly and oligomerization of Aβ has been an important strategy for designing AD therapeutics. In parallel, research into the metallobiology of AD has shown that Zn2+ can strongly modulate the aggregation of Aβ in vitro and both promote and inhibit the neurotoxicity of Aβ, depending on the experimental conditions. Thus, successful inhibitors of Aβ self-assembly may have to inhibit the toxicity not only of Aβ oligomers themselves but also of Aβ-Zn2+ complexes. However, there has been relatively little research investigating the effects of Aβ self-assembly and toxicity inhibitors in the presence of Zn2+. Our group has characterized previously a series of Aβ42 C-terminal fragments (CTFs), some of which have been shown to inhibit Aβ oligomerization and neurotoxicity. Here, we asked whether three CTFs shown to be potent inhibitors of Aβ42 toxicity maintained their activity in the presence of Zn2+. Biophysical analysis showed that the CTFs had different effects on oligomer, β-sheet, and fibril formation by Aβ42-Zn2+ complexes. However, cell viability experiments in differentiated PC-12 cells incubated with Aβ42-Zn2+ complexes in the absence or presence of these CTFs showed that the CTFs completely lost their inhibitory activity in the presence of Zn2+ even when applied at 10-fold excess relative to Aβ42. In light of these results, we tested another inhibitor, the molecular tweezer CLR01, which coincidentally had been shown to have a high affinity for Zn2+, suggesting that it could disrupt both Aβ42 oligomerization and Aβ42-Zn2+ complexation. Indeed, we found that CLR01 effectively inhibited the toxicity of Aβ42-Zn2+ complexes. Moreover, it did so at a lower concentration than needed for inhibiting the toxicity of Aβ42 alone. In agreement with these results, CLR01 inhibited β-sheet and fibril formation in Aβ42-Zn2+ complexes. Our data suggest that, for the development of efficient therapeutic agents, inhibitors of Aβ self-assembly and toxicity should be examined in the presence of relevant metal ions and that molecular tweezers may be particularly attractive candidates for therapy development.
Insights
Alzheimer's disease (AD) drug development requires targeting amyloid-beta (Aβ) self-assembly. New research shows Aβ-zinc complexes reduce the effectiveness of some inhibitors, but molecular tweezers like CLR01 show promise in combating Aβ toxicity in the presence of zinc.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Amyloid-beta (Aβ) oligomers are implicated in Alzheimer's disease (AD) pathogenesis.
- Aβ self-assembly inhibition is a key therapeutic strategy for AD.
- Zinc ions (Zn2+) significantly influence Aβ aggregation and neurotoxicity, complicating therapeutic development.
Purpose of the Study:
- To investigate whether previously identified inhibitors of Aβ42 toxicity retain efficacy in the presence of Zn2+.
- To evaluate the potential of molecular tweezers, specifically CLR01, as inhibitors of Aβ-Zn2+ complex toxicity.
Main Methods:
- Biophysical analysis of Aβ42-Zn2+ complex formation and structural changes in the presence of inhibitors.
- Cell viability assays using differentiated PC-12 cells exposed to Aβ42-Zn2+ complexes and inhibitors.
- Characterization of CLR01's effect on Aβ42-Zn2+ complex aggregation and toxicity.
Main Results:
- Previously effective Aβ42 inhibitors lost significant neuroprotective activity when tested against Aβ42-Zn2+ complexes.
- The molecular tweezer CLR01 demonstrated potent inhibition of Aβ42-Zn2+ complex toxicity, even at lower concentrations than required for Aβ42 alone.
- CLR01 effectively inhibited β-sheet and fibril formation in Aβ42-Zn2+ complexes, indicating disruption of aggregation.
Conclusions:
- Therapeutic agents targeting Aβ self-assembly must be evaluated in the presence of biologically relevant metal ions like Zn2+.
- Molecular tweezers, such as CLR01, represent a promising class of therapeutics for Alzheimer's disease due to their ability to target both Aβ and its metal complexes.
- The findings underscore the importance of considering metallobiology in the design of effective Alzheimer's disease treatments.
Related Concept Videos
Metal-Ligand Bonds
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
Complexation Equilibria: Factors Influencing Stability of Complexes
EDTA: Auxiliary Complexing Reagents
EDTA: Chemistry and Properties
Extraction: Advanced Methods
Complexation Equilibria: The Chelate Effect


